Tarsus Pharmaceuticals
TARS
44 hedge funds and large institutions have $277M invested in Tarsus Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 44 → 44 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
1.09% less ownership
Funds ownership: 63.65% → 62.56% (-1.1%)
27% less capital invested
Capital invested by funds: $378M → $277M (-$101M)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$576K |
| 2 |
Morgan Stanley
New York
|
+$501K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$242K |
| 4 |
State Street
Boston,
Massachusetts
|
+$190K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$94.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$7.54M |
| 2 |
ACM
Altium Capital Management
New York
|
-$2.04M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.72M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$889K |
| 5 |
JG
Jefferies Group
New York
|
-$495K |
TARS Hedge Fund Activity: Q3 2021 in Review
44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2021, worth a combined $277M — down 27% from $378M a quarter earlier.
Fund positioning in TARS was balanced in Q3 2021: 6 funds opened new positions, 6 closed out, 10 added to existing stakes and 16 trimmed.
The largest buyer was SG Americas Securities, adding an estimated $576K. The largest seller was Sands Capital Management, exiting entirely with an estimated $7.54M sold.
- 44 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $277M of Tarsus Pharmaceuticals stock for Q3 2021, down 27% quarter-over-quarter.
- 6 funds opened new Tarsus Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of 0 holders.
- The largest Tarsus Pharmaceuticals buyer in Q3 2021 was SG Americas Securities, an estimated $576K added.
- The largest Tarsus Pharmaceuticals seller in Q3 2021 was Sands Capital Management, an estimated $7.54M sold.
Based on aggregated 13F filings for Q3 2021.